Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study

Professor Peter Schmid presented the overall survival results from the phase 3 KEYNOTE-522 study at ESMO 2024 Congress. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC.

Video: https://medicaldigest.org/scientific-contents/interview:neoadjuvant-pembrolizumab-or-placebo-plus-chemotherapy-followed-adjuvant-pembrolizumab-or-placebo-high-risk-early-stage-tnbc-overall-survival-results-phase-3-keynote-522-study